No radiation therapy =<  weeks before pre-registration

No prior radiation therapy for bone metastasis within  weeks, any other radiation therapy within  weeks prior to registration

Washout period should be at least  weeks for prior chemotherapy or radiation therapy

Subject is within  weeks of completion of radiation.

At least  weeks since prior treatment (chemotherapy, radiation therapy, hormonal therapy)

Radiation therapy for breast cancer within  weeks of dosing and planning to have radiation therapy during participation in this study.

Radiation therapy within  weeks of enrollment

At least  weeks after the last dose of chemotherapy or radiation therapy;  weeks for mitoxantrone or mitomycin therapy

Prior radiation therapy within  weeks prior to the first dose of the study regimen

Any radiation therapy in prior  weeks

Radiation therapy less than or equal to  weeks prior to registration

Prior radiation therapy or chemotherapy within  weeks prior cycle , day , monoclonal antibody therapy within  weeks

Radiation therapy for bone metastasis within  weeks, any other external radiation therapy within  weeks before planned first dose of study drug. Systemic treatment with radionuclides within  weeks before planned first dose of study drug. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible

Had therapeutic radiation therapy or major surgery within  weeks before study drug treatment or palliative radiation therapy within  weeks before study drug treatment.

Radiation therapy for bone metastasis within  weeks, any other external radiation therapy within  weeks before the first dose of study treatment. Systemic treatment with radionuclides within  weeks before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible

Participants must be >=  weeks since any prior radiation, including central nervous system (CNS) radiation

Radiation therapy within  weeks of study treatment

Participants must be >=  weeks since any prior radiation, including central nervous system (CNS) radiation

Radiation within  weeks prior to registration

At least  weeks (wks) since prior radiation

Radiation therapy in the previous  weeks prior to first dose.

>=  weeks off radiation therapy

Recent prior therapy:\r\n* Systemic chemotherapy =<  weeks ( weeks for clofarabine or nitrosoureas) or radiation therapy =<  weeks prior to apheresis;\r\n** Exceptions:\r\n*** There is no time restriction in regard to prior intrathecal chemotherapy provided there is complete recovery from any acute toxic effects of such;\r\n*** Subjects receiving hydroxyurea may be enrolled provided there has been no increase in dose for at least  weeks prior to starting apheresis;\r\n*** Patients who are on standard ALL maintenance type chemotherapy (vincristine, -mercaptopurine, oral methotrexate, or a tyrosine kinase inhibitor for patients with Philadelphia chromosome positive [Ph+] ALL) may be enrolled provided that chemotherapy is discontinued at least  week prior to apheresis\r\n*** Subjects receiving steroids may be enrolled, provided there has been no increase in dose for at least  week prior to starting apheresis;\r\n*** For radiation therapy: radiation therapy must have been completed at least  weeks prior to enrollment (including CNS radiation), with the exception that there is no time restriction if the volume of bone marrow treated is less than % and also the subject has measurable/evaluable disease outside the radiation port

Radiation therapy to a study target tumor within  year prior to enrollment, or any radiation therapy within  weeks prior to enrollment

Minimum interval since completion of radiation treatment is  weeks

STRATUM A: Participants must have had their last fraction of radiation at least  weeks prior to study enrollment; participants who received radiation therapy for palliation must have had their last fraction of radiation at least  weeks prior to study enrollment

STRATUM B: Participants must have had their last fraction of radiation at least  weeks prior to study enrollment; participants who received radiation therapy for palliation must have had their last fraction of radiation at least  weeks prior to study enrollment

STRATUM C: Participants must have had their last fraction of radiation at least  weeks prior to study enrollment; participants who received radiation therapy for palliation must have had their last fraction of radiation at least  weeks prior to study enrollment

Treatment with radiation therapy within  weeks

Radiation therapy within  weeks (if single fraction of radiotherapy within  weeks) of enrollment (day  visit)

Subjects who have had radiation therapy within  weeks prior to first dose of drug

Subjects must be at least  weeks from prior anti-lymphoma therapy (including radiation therapy)

Prior major surgical procedure or radiation therapy within  weeks of the first dose of study treatment (this does not include limited course of radiation used for management of bone pain within  days of first dose of study therapy)

Radiation treatment must begin >=  weeks and =<  weeks after surgery

Radiation therapy for bone metastasis within  weeks, any other external radiation therapy within  weeks before the first dose of study treatment; systemic treatment with radionuclides within  weeks before the first dose of study treatment; subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible

Patients must be >=  weeks from most recent systemic therapy or radiation therapy

Radiation therapy (other than palliative radiation to bony metastases) as cancer therapy within  weeks prior to initiation of study treatment

Radiation therapy within  weeks (within  weeks, if single fraction of radiotherapy) before day .

Patients who have had chemotherapy or radiation therapy within  weeks prior to beginning protocol therapy

No prior radiation therapy or radionuclide therapy for the treatment of metastasis within four weeks prior to enrollment

Radiation therapy within  weeks prior to randomization and not recovered to baseline from any AE due to radiation

Any chemotherapy or radiation therapy within  weeks of the first dose of study drug

The following minimum intervals are required between prior treatment and initiation of study therapy:\r\n* Cytotoxic chemotherapy:  weeks\r\n* Molecularly targeted therapy or immunotherapy:  weeks\r\n* Conventional fractionated radiation therapy:  weeks\r\n* Stereotactic radiation therapy:  week\r\n* Major surgery:  weeks

Major surgery <  weeks or radiation therapy <  weeks of starting the study treatment; prior palliative radiotherapy to metastatic lesion(s) is permitted, provided there is at least one measurable lesion that has not been irradiated\r\n* Radiotherapy is defined as whole brain radiation, external beam radiation therapy (EBRT), or stereotactic brain radiation (SBRT)

Radiation therapy within four weeks prior to administration of the first dose of ARQ 

Radiation therapy within  weeks of study enrollment (exception is radiotherapy expansion arm which requires radiation treatment within  week period)

Local Skin Radiation Therapy (< % skin surface):  weeks

Radiation therapy for bone metastasis within  weeks, any other external radiation therapy within  weeks before the first dose of study treatment; systemic treatment with radionuclides within  weeks before the first dose of study treatment; subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible

Radiation therapy for bone metastases within  weeks, other external radiation therapy within  weeks of enrollment

Radiation or chemotherapy within  weeks of enrollment

Subject has had radiation therapy to the tumor selected for research collection, or has had radiation therapy to any site within  weeks prior to study day 

Patients who have had chemotherapy or radiation =<  weeks of registration

Untreated central nervous system metastases; patients are eligible if they are clinically stable, off all steroids after cranial irradiation (whole brain radiation therapy, focal radiation therapy, stereotactic radio surgery) ending at least  weeks prior to enrollment, or after surgical resection performed at least  weeks prior to enrollment

Radiation therapy for bone metastasis within  weeks, or any other external radiation therapy within  weeks before the first dose of study treatment; subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible

Radiation therapy must begin within  weeks of surgery

>  weeks since prior radiation, surgery or chemotherapy

Minimum interval since completion of radiation treatment is  weeks

Screening magnetic resonance imaging (MRI) must be obtained at least  weeks after any salvage surgery, and at least  weeks after radiation therapy, or at least  weeks after radiation for a new lesion outside the prior primary radiation field unless relapse is confirmed by tumor biopsy or new lesion outside of radiation field, or if there are two MRIs confirming progressive disease that are  weeks apart

Radiation therapy within  weeks before the first dose of study treatment

At least  weeks since the completion of radiation therapy to a total of >=  Gy

Patients must have failed prior radiation therapy and must have an interval of greater than or equal to  weeks from the completion of radiation therapy to registration; except if patients underwent surgery within  weeks and pathology is consistent with recurrent tumor

>  weeks since prior radiation, surgery or chemotherapy

Radiation Therapy: Hepatic radiation within  weeks of PV- administration.

Prior radiation within  weeks of study registration

Conventional chemotherapy or radiation within  weeks.

Conventional chemotherapy or radiation within  weeks.

Radiation therapy within  weeks of Day 

No radiation therapy to targeted (most painful) tumors in the past two weeks

Radiation therapy for bone metastasis within  weeks, any other external radiation therapy within  weeks before the first dose of study treatment; systemic treatment with radionuclides within  weeks before the first dose of study treatment; subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible

Subjects who have had radiation therapy within  weeks prior to first dose of drug

Prior chemoembolization or radiation therapy (including Y) must be performed at least  weeks before study enrollment

Has had radiation therapy within  weeks of the first protocol treatment

At least  weeks from completion of radiation therapy except if there is unequivocal evidence for tumor recurrence in which case at least  weeks

Radiation therapy within  weeks prior to enrollment

Recent prior therapy:\r\n* Systemic chemotherapy =<  weeks ( weeks for nitrosoureas) or radiation therapy =<  weeks prior to apheresis; exceptions: \r\n** There is no time restriction in regard to prior intrathecal chemotherapy provided there is complete recovery from any acute toxic effects of such; \r\n** Subjects receiving hydroxyurea may be enrolled provided there has been no increase in dose for at least  weeks prior to starting apheresis; \r\n** Patients who relapse while receiving standard ALL maintenance chemotherapy will not be required to have a waiting period before entry onto this study provided they meet all other eligibility criteria; \r\n** Subjects receiving steroid therapy at physiologic replacement doses only are allowed provided there has been no increase in dose for at least  weeks prior to starting apheresis; \r\n** For radiation therapy: radiation therapy must have been completed at least  weeks prior to enrollment, with the exception that there is no time restriction if the volume of bone marrow treated is less than % and also the subject has measurable/evaluable disease outside the radiation port

Radiation therapy within  weeks prior to randomization on this study and not recovered to baseline from adverse events due to radiation therapy

Subject has radiation therapy within  weeks prior to the first study dose.

Radiation therapy within  weeks prior to screening.

Last dose of prior chemotherapy, radiation therapy, or investigational agents occurred at least  weeks before the start of therapy;

Radiation therapy within  weeks of registration

Radiation therapy (except palliative to relieve bone pain) within  weeks of study entry. Whole brain radiation must have completed at least  weeks prior to study entry.

Radiation therapy within  weeks ( weeks for radiation for bone metastases) or radionuclide treatment within  weeks of randomization.

Prior radiation therapy within  weeks of infusion

At least  weeks from end of radiation therapy

Radiation therapy (other than radiation to bony metastases) as cancer therapy </=  weeks before study treatment

Therapeutic radiation therapy or major surgery within  weeks before study drug treatment or palliative radiation therapy within  weeks before study drug treatment

Radiation therapy within  weeks prior to enrollment

Radiation therapy within  weeks before randomisation.

Has received prior treatment including radiation and chemotherapy, with radiation completed >  weeks prior to Day  (or ?  weeks if the recurrence is outside of the prior radiation field).

Subject has radiation therapy within  weeks prior to the first study dose.

Radiation therapy for bone metastases within  weeks, other external radiation therapy within  weeks of enrollment

Radiation therapy to bone within  weeks before enrollment;

Radiation therapy =<  weeks prior to randomization

Radiation or chemotherapy within  weeks of enrollment

Patient has had radiation therapy within  weeks of beginning study treatment

No prior systemic therapy, immunotherapy, investigational agent, or radiation therapy within the last  weeks. Radiation therapy for symptomatic relief is allowed within the last  weeks.

Conventional chemotherapy or radiation within  weeks.

No radiation therapy =<  weeks prior to registration

Patients must be at least two weeks from prior radiation therapy (RT)

At least  weeks since prior chemotherapy or radiation therapy

Chemotherapy, radiation therapy, or ablative therapy within  weeks of randomization

Radiation therapy within  weeks before first dose. Radioimmunotherapy within  weeks before first dose.

Subject has radiation therapy within  weeks prior to the first study dose.

No prior radiation therapy or radionuclide therapy for the treatment of metastasis within four weeks prior to enrollment

Patients must have failed prior radiation therapy and must have an interval of greater than or equal to  weeks from the completion of radiation therapy to study entry

Radiation therapy within  weeks prior to first dose

Radiation therapy within  weeks prior to first dose. Localized radiation therapy within  week prior to first dose.

Untreated central nervous system metastases; patients are eligible if they are clinically stable, off all steroids after cranial irradiation (whole brain radiation therapy, focal radiation therapy, stereotactic radio surgery) ending at least  weeks prior to enrollment, or after surgical resection performed at least  weeks prior to enrollment

Prior radiation therapy within  weeks and radionuclide therapy within  weeks of enrollment

Concomitant anticancer therapy, immunotherapy, or radiation therapy (no radiation within prior  weeks)

Concomitant anticancer therapy, immunotherapy, or radiation therapy (no radiation within prior  weeks)

If palliative radiation to non-breast sites is required prior to initiation of systemic therapy, scans may be completed within  weeks prior to or  weeks following the start of radiation therapy

Major surgery, locoregional therapy, or radiation therapy within four weeks of the first dose of ARQ 

Radiation therapy =<  weeks prior to registration

Prior palliative radiation therapy less than  weeks prior to administration of study treatment or prior whole brain radiation therapy (WBRT) less than  weeks prior to study treatment

Radiation treatment within  weeks.

Radiation therapy within  weeks prior to the first dose of study medication

Therapeutic radiation therapy or major surgery within  weeks before study drug treatment; or palliative radiation within  weeks before study drug treatment

Ongoing radiation therapy or radiation therapy administered within  weeks of enrollment

At least  weeks from completion of radiation therapy except if there is unequivocal evidence for tumor recurrence in which case at least  weeks

Radiation therapy or surgery in the past  weeks

=<  weeks since radiation therapy

Radiation therapy within  weeks.

Radiation and surgery within  weeks prior to treatment in this study

Subject has had radiation therapy within  weeks prior to the first study dose.

Must have stable neurologic status following local therapy (surgery or radiation) for at least  weeks after completion of the definitive therapy AND

Subject has had radiation therapy within  weeks prior to the first study dose

Radiation treatment within  weeks.

Radiation therapy or immunotherapy in the previous four weeks; localized radiation therapy within  week prior to first dose

Radiation therapy within  weeks before first dose

Radiation therapy within  weeks (if single fraction of radiotherapy within  weeks) of Day  visit, or radionuclide therapy within  weeks of Day 

Radiation therapy to any Study Lesion within  weeks of initial study treatment.

The subject has received radiation therapy within  weeks (=<  weeks for palliative radiation therapy)

Radiation therapy for bone or brain metastasis within  weeks, any other external radiation therapy within  weeks of first dose of study drug; systemic treatment with radionuclides within  weeks; subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible

Patients must be at least  weeks from the completion of any radiation therapy

Radiation therapy as cancer therapy within  weeks, or palliative radiation to bony metastases within  weeks, prior to starting study treatment

Interval from radiation therapy at least  weeks and no more than  year

Treatment with radiation within  weeks

Prior radiation therapy of the index tumor < weeks prior to screening

At least  weeks since prior chemotherapy, radiation treatment and/or surgery

Focal radiation ?  weeks

Radiation therapy for bone metastasis within  weeks, any other external radiation therapy within  weeks before randomization. Systemic treatment with radionuclides within  weeks before randomization. Subjects with complications from prior radiation therapy are not eligible and AEs must return to baseline or ? Grade .

 weeks since last chemotherapy or therapeutic radiation therapy

Prior chemotherapy within  weeks; prior immunotherapy or biologic therapy within  weeks; prior radiation therapy within  weeks

Therapeutic radiation therapy or major surgery within  weeks before study drug treatment or palliative radiation therapy within  weeks before study drug treatment.

chemotherapy or radiation therapy within three weeks